NYLIM
BEAM icon

New York Life Investment Management’s Beam Therapeutics BEAM Stock Holding History

New York Life Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,734
Closed -$355K – 912
2024
Q1 		$355K Buy
+10,734
New +$334K ﹤0.01% 1269

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

New York Life Investment Management's BEAM Position: Q2 2024 in Review

New York Life Investment Management sold out of Beam Therapeutics (BEAM) in Q2 2024, closing a stake of 10,734 shares — an estimated $355K sold.

New York Life Investment Management first reported a position in BEAM in Q1 2024 and held it in 1 quarter. The position peaked at $355K in Q1 2024. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • New York Life Investment Management reported no remaining Beam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 10,734 Beam Therapeutics shares in Q2 2024, an estimated $355K.
  • New York Life Investment Management first reported a position in Beam Therapeutics in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Beam Therapeutics position peaked at $355K in Q1 2024.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.